{"id":"F2006L03978","name":"National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 3 of 2007)","slug":"national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-3-of-2007","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":60917,"registerId":"commonwealth-F2006L03978-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 3 of 2007)","content":"COMMONWEALTH OF AUSTRALIA\n\nNational Health Act 1953\n\nPHARMACEUTICAL BENEFITS\n\nDECLARATION UNDER SUBSECTION 85(2AA)\n\nNo. PB 3 OF 2007\n\nI, JOAN CORBETT, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing and Delegate of the Minister for Health and Ageing, having in accordance with subsection 85(2AB) of the National Health Act 1953 obtained the advice of the Pharmaceutical Benefits Advisory Committee, pursuant to subsection 85(2AA) of the National Health Act 1953 hereby make the following Declaration:\n\n1. This Declaration commences on 1 January 2007.\n\n2. The drugs and medicinal preparations specified in the Schedule to this Declaration shall cease to be drugs and medicinal preparations to which Part VII of the National Health Act 1953 applies.\n\nTHE SCHEDULE\n\nMoxifloxacin Hydrochloride\n\nDated this 1st day of December 2006.\n\nJOAN CORBETT\n\nAssistant Secretary\n\nPharmaceutical Evaluation Branch\n\nDepartment of Health and Ageing\n\nDelegate of the Minister for Health and Ageing","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":2687},"content_quality":"ok","complexity_score":1,"scope_assessment":{"changed":false,"description":"This declaration performs its precise statutory function: removing a specified pharmaceutical from PBS coverage following expert committee advice. No expansion beyond the original administrative purpose."},"complexity_factors":["Single substantive provision (delisting one specific drug)","No interpretation section or defined terms","Direct exercise of delegated power without conditional triggers","Minimal cross-referencing (only cites empowering provisions in the National Health Act)","Straightforward commencement mechanism"],"plain_english_summary":"This instrument delists the antibiotic moxifloxacin hydrochloride (Avelox) from Australia’s Pharmaceutical Benefits Scheme, so from 1 January 2007 patients must pay the full unsubsidised pharmacy price instead of the usual PBS co‑payment.\n\nThe change was made administratively by a Health Department delegate after advice from the Pharmaceutical Benefits Advisory Committee — a routine but consequential step that shifts costs to patients and prompts clinicians to seek alternatives."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-3-of-2007","history":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-3-of-2007/history","analysis":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-3-of-2007/analysis","conflicts":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-3-of-2007/conflicts","importantCases":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-3-of-2007/important-cases","documents":"/api/acts/national-health-act-1953-declaration-under-subsection-85-2aa-no-pb-3-of-2007/documents"}}